SARCOMATOID RENAL CELL CARCINOMA

This phase 3 trial tests whether adding the drug cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will take part. The goal is to see if the combination wor…

This early-phase study tests two or three drugs together (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced cancers of the urinary and genital systems that have spread. The main goals are to find the safest dose and understand side effects. About 152 adul…

This study tests whether adding the immunotherapy drug nivolumab before and after kidney cancer surgery can stop the cancer from returning. About 819 people with localized kidney cancer took part. The goal is to see if this approach improves how long patients stay cancer-free com…

This early-stage trial tests whether adding camu camu, a prebiotic berry, to standard immunotherapy (nivolumab and ipilimumab) can improve treatment for advanced kidney cancer. About 31 people with metastatic clear-cell or sarcomatoid kidney cancer will receive the combination. T…

This study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug works better at slowing cancer growth and has fewer side effects. About 32 par…

This study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 adults will take the drugs until their disease gets worse or side effects become too severe. The goal is to see if…